Results 131 to 140 of about 3,447 (196)

From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease: Out with the Old, in with the New. [PDF]

J Clin Med
Alabdul Razzak I, Noureddin M, Trivedi HD.   +2 more
europepmc   +1 more source

TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial. [PDF]

Nat Med
Noureddin M, Alkhouri N, Lawitz EJ, Kowdley KV, Loomba R, Lee L, Jones C, Schlegel A, Marmon T, Anderson K, Li Y, Quirk E, Harrison SA.   +12 more
europepmc   +1 more source

The Global Burden of Alcohol-associated Cirrhosis and Cancer in Young and Middle-aged Adults. [PDF]

Clin Gastroenterol Hepatol
Danpanichkul P, Ng CH, Tan DJH, Wijarnpreecha K, Huang DQ, Noureddin M, Young Alcohol Disease Collaborative.   +6 more
europepmc   +1 more source

Increased MASH-associated liver cancer in younger demographics. [PDF]

Hepatol Commun
Danpanichkul P, Danpanichkul P, Pang Y, Suparan K, Auttapracha T, Sirimangklanurak S, Attia AM, Thimphitthaya C, Ni Law MS, Yu Z, Soliman MA, Polpichai N, Kanitthamniyom C, Kim D, Noureddin M, Singal AG, Wijarnpreecha K, Yang JD.   +17 more
europepmc   +1 more source

Global patterns of utilization of noninvasive tests for the clinical management of metabolic dysfunction-associated steatotic liver disease. [PDF]

Hepatol Commun
Allen AM, Lazarus JV, Alkhouri N, Noureddin M, Wong VW, Tsochatzis EA, de Avila L, Racila A, Nader F, Mark HE, Henry L, Stepanova M, Castera L, Younossi ZM.   +13 more
europepmc   +1 more source

Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis. [PDF]

Hepatology
Koh B, Xiao J, Ng CH, Law M, Gunalan SZ, Danpanichkul P, Ramadoss V, Sim BKL, Tan EY, Teo CB, Nah B, Teng M, Wijarnpreecha K, Seko Y, Lim MC, Takahashi H, Nakajima A, Noureddin M, Muthiah M, Huang DQ, Loomba R.   +20 more
europepmc   +1 more source

Conatus of machine

openaire   +1 more source

Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States. [PDF]

Clin Mol Hepatol
Danpanichkul P, Pang Y, Mahendru T, Tothanarungroj P, Díaz LA, Arab JP, Jatupornpakdee P, Muthiah MD, Duangsonk K, Choi WM, Huang DQ, Kim D, Noureddin M, Wijarnpreecha K, Liangpunsakul S, Singal AG, Yang JD.   +16 more
europepmc   +1 more source

Global Trend of MASH-associated Liver Cancer: A Systematic Analysis From the Global Burden of Disease 2021. [PDF]

Clin Gastroenterol Hepatol
Danpanichkul P, Suparan K, Kaeosri C, Jatupornpakdee P, Attia AM, Suenghataiphorn T, Thongpiya J, Sukphutanan B, Huang DQ, Noureddin M, Singal AG, Wijarnpreecha K, Yang JD.   +12 more
europepmc   +1 more source

Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis. [PDF]

Hepatology
Ratziu V, Francque S, Behling CA, Cejvanovic V, Cortez-Pinto H, Iyer JS, Krarup N, Le Q, Sejling AS, Tiniakos D, Harrison SA.   +10 more
europepmc   +1 more source